Nov 18, 2021 15:28 JST

Source: Eisai

Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award

TOKYO, Nov 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association.


The "Most Liked!" IR Award has been newly created for commemorating the 25th anniversary of the Best IR Award in 2020. The award is designed to reflect the viewpoints of companies that applied for the IR Award based on their voting, share their proactive IR experiences, and realize best practices. The theme for 2021 is "IR activities contributing sustainability," awarding companies that have actively promoted information disclosure and their dialogue with investors on sustainability-related matters. Of the companies that applied for the 2021 IR Award, 178 companies entered the 'Most Liked!" IR Award and the top 17 companies, including Eisai, were selected based on a mutual vote by the candidate companies.

For further details, please visit the JIRA website:

Eisai has focused on disseminating information regarding financial capital and non-financial capital value relevance that link to corporate value for longer-term as well as continuously through publicizing the results of the analysis of the correlation between ESG-related indicators and PBR (Price Book-value Ratio) , holding discussion meetings with investors, or publishing the Eisai Value Creation Report. The award was given to Eisai with "empathy" for Eisai's efforts to visualize ESG.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
January 19 2022 16:36 JST
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
January 19 2022 09:06 JST
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
January 17 2022 10:44 JST
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
January 13 2022 12:26 JST
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
January 06 2022 10:09 JST
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
December 24 2021 08:26 JST
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
December 21 2021 09:23 JST
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
December 20 2021 12:35 JST
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium
December 06 2021 11:30 JST
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
November 30 2021 09:13 JST
More Press release >>

Latest Press Release

More Latest Release >>